Moderna Inc. [MRNA] Chief Executive Officer makes an insider purchase of 40,000 shares worth 5.48 million.

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Moderna Inc. shares valued at $5,484,458 were sold by Bancel Stephane on Sep 15. At $137.11 per share, Bancel Stephane sold 40,000 shares. The insider’s holdings dropped to 5,411,946 shares worth approximately $672.81 million following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Also, Bancel Stephane sold 10,000 shares, netting a total of over 1,386,200 in proceeds. Following the sale of shares at $138.62 each, the insider now holds 6,714,880 shares.

Before that, Bancel Stephane had sold 40,000 shares from its account. In a trade valued at $5,552,944, the Chief Executive Officer traded Moderna Inc. shares for $138.82 each. Upon closing the transaction, the insider’s holdings decreased to 40,000 shares, worth approximately $672.81 million.

As published in a research note from Deutsche Bank on September 08, 2022, Moderna Inc. [MRNA] has been rated up from a Hold to a Buy and the price target has been revised to $165. This represents a 24.65% premium over Thursday’s closing price. Analysts at Redburn upgraded the stock from ‘”a Sell”‘ to ‘”a Neutral”‘ outlook in a report released in early February. As of January 26, 2022, Deutsche Bank has increased its “Sell” rating to a “Hold” for MRNA. Earlier on January 21, 2022, BofA Securities upgraded its rating. Their new recommendation was “a Neutral” for MRNA stock which previously was a “an Underperform”.

Analyzing MRNA’s Price Performance

On Thursday, Moderna Inc. [NASDAQ: MRNA] plunged -1.15% to $124.32. The stock’s lowest price that day was $122.90, but it reached a high of $126.08 in the same session. During the last five days, there has been a drop of approximately -8.49%. Over the course of the year, Moderna Inc. shares have dropped approximately -51.05%. Shares of the company reached a 52-week high of $249.42 on 01/03/22 and a 52-week low of $115.61 on 06/13/22. A 50-day SMA is recorded $153.07, while a 200-day SMA reached $165.40. Nevertheless, trading volume fell to 3.45 million shares from 8.55 million shares the previous day.

Support And Resistance Levels for Moderna Inc. (MRNA)

According to the 24-hour chart, there is a support level at 122.79, which, if violated, would cause prices to drop to 121.25. In the upper region, resistance lies at 125.97. The next price resistance is at 127.61. RSI (Relative Strength Index) is 36.41 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -7.65, which suggests the price will decrease in the coming days. Percent R is at 93.51%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Moderna Inc. subject to short interest?

Stocks of Moderna Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 1.53 million shares to 16.29 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 14.76 million shares. A jump of 9.39% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.87 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.87.

Which companies own the most shares of Moderna Inc. (MRNA)?

According to Baillie Gifford & Co. filings, the company currently owns 45,559,791 shares, which is about 11.65% of the total MRNA shares outstanding. The investor’s shares have plunged by -69,435 from its previous 13-F filing of 45629226.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $3,470,472,880. BlackRock Fund Advisors reduced a -11.68% interest valued at $2.32 billion while SSgA Funds Management, Inc. sold a -80,550 stake. A total of 17,466 shares of Moderna Inc. were sold by Thélème Partners LLP during the quarter, and -98,663 were sold by Geode Capital Management LLC. In its current portfolio, Coatue Management LLC holds 5,706,331 shares valued at $754.78 million.

LEAVE A REPLY

Please enter your comment!
Please enter your name here